ACE inhibitors compete with bradykinin for ACE binding sites, resulting in reduced bradykinin degradation and an increased amount of active bradykinin in the circulation and tissues causing angioedema and cough in patients on these medications [9]. The gene discussed is ACE; the disease is angioedema.